Search

Your search keyword '"Libe, Rossella"' showing total 124 results

Search Constraints

Start Over You searched for: Author "Libe, Rossella" Remove constraint Author: "Libe, Rossella"
124 results on '"Libe, Rossella"'

Search Results

1. Sunitinib for metastatic progressive phaeochromocytomas and paragangliomas: results from FIRSTMAPPP, an academic, multicentre, international, randomised, placebo-controlled, double-blind, phase 2 trial

2. Adjuvant mitotane versus surveillance in low-grade, localised adrenocortical carcinoma (ADIUVO): an international, multicentre, open-label, randomised, phase 3 trial and observational study

3. Recommandations du réseau national ENDOCAN-COMETE pour la prise en charge des phéochromocytomes et paragangliomes métastatiques

5. Recommandations conjointes du réseau National ENDOCAN-COMETE, de l’Association francophone de chirurgie endocrinienne et de la Société française d’urologie pour la prise en charge du carcinome corticosurrénalien

7. KDM1A inactivation causes hereditary food-dependent Cushing syndrome

8. Effectiveness of temozolomide treatment in SDHx mutant and wildtype metastatic pheochromocytoma and paraganglioma - results of a European restrospective multicentre study

9. Decrease in anticortisolic drmg osilodrostat plasma exposure in patients treated with mitotane for adrenocortical carcinoma

11. Urine steroid metabolomics for the differential diagnosis of adrenal incidentalomas in the EURINE-ACT study: a prospective test validation study

13. Clinicopathological description of 43 oncocytic adrenocortical tumors: importance of Ki-67 in histoprognostic evaluation

15. Decrease in anticortisolic drug osilodrostat plasma exposure in patients treated with mitotane for an adrenocortical carcinoma

16. Whole blood transcriptomic signature of Cushing's syndrome

17. Tumor microenvironment of adrenocortical carcinoma dissected by single-cell RNA-sequencing

18. Prolonged exposure to target mitotane concentrations is associated with better recurrence-free survival in patients with adrenocortical carcinoma on adjuvant treatment

19. C-peptide level concomitant with hypoglycemia gives better performances than insulin for the diagnosis of endogenous hyperinsulinism: a monocentric study of 159 fasting trials

20. Corticosurrénalome et grossesse

21. Comprehensive Pan-Genomic Characterization of Adrenocortical Carcinoma

22. Data from Functional Phosphodiesterase 11A Mutations May Modify the Risk of Familial and Bilateral Testicular Germ Cell Tumors

23. Supplementary Table 1 from Functional Phosphodiesterase 11A Mutations May Modify the Risk of Familial and Bilateral Testicular Germ Cell Tumors

24. Supplementary Table 2 from Functional Phosphodiesterase 11A Mutations May Modify the Risk of Familial and Bilateral Testicular Germ Cell Tumors

26. Real-life efficacy and predictors of response to immunotherapy in pituitary tumors: a cohort study

30. Transcriptome in paraffin samples for the diagnosis and prognosis of adrenocortical carcinoma

31. Integrated genomics reveals the molecular classification of Primary Bilateral Macronodular Adrenal Hyperplasia (PBMAH), correlating with specific profiles of illegitimate receptors expression and identifies KDM1A as the genetic cause of food-dependent Cushing syndrome

32. Positive Correlation Between [18F]-fluorodeoxyglucose (FDG) Uptake and Tumor-proliferating Antigen Ki-67 Expression in Adrenocortical Carcinomas

35. Pre-operative hypercortisolism and post-operative adrenal insufficiency in pheochromocytomas: a single center retrospective analysis of 168 patients

36. PDE11A4 (Phosphodiesterase 11 A4) is a modulator of the primary bilateral macronodular adrenal hyperplasia (PBMAH) phenotype: genotype/phenotype analysis of a cohort of 354 patients analysed by next-generation sequencing (NGS)

37. Results of the ADIUVO Study, the First Randomized Trial on Adjuvant Mitotane in Adrenocortical Carcinoma Patients

38. Modified GRAS Score for Prognostic Classification of Adrenocortical Carcinoma: An ENSAT Multicentre Study

40. Steroid Profiling in Adrenocortical Carcinoma Reveals Mitotane as a Strong Inducer of CYP3A4 and Inhibitor of 5α-Reductase with Major Implications for Cortisol and Androgen Metabolism

42. Identification of transcriptome profiles in paraffin samples using 3’ RNA-sequencing for the prognostic assessment of adrenocortical carcinoma

43. Identification of clinical parameters predictive of ARMC5 mutation in a large cohort of primary bilateral macronodular adrenal hyperplasia (PBMAH) patients.

45. Intratumor heterogeneity of prognostic DNA-based molecular markers in adrenocortical carcinoma

46. Retrovirus-like long-terminal repeat DQ-LTR13 and genetic susceptibility to type 1 diabetes and autoimmune Addison's disease

47. Contribution of morphological and functional liver imaging to differentiate liver metastases of adrenocortical carcinoma from those of neuroendocrine tumors in a woman with a final diagnosis of multiple endocrine neoplasia type 1

48. Molecular events in a large series of advanced stage III-IV adrenocortical cancer: looking for new therapeutic options

49. The French COMETE-Cancer network for adrenal cancer: 10 years of activity as part of a national plan for clinical care of rare cancers

50. Genetic predisposition to Primary Bilateral Macronodular Adrenal Hyperplasia (PBMAH): next generation sequencing ARMC5, NR3C1 (glucocorticoid receptor) and PDE11A4 (phosphodiesterase 11) in 389 patients

Catalog

Books, media, physical & digital resources